On Wednesday, Cencora, Inc.’s (NYSE:COR) fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion. The sales jump reflects a 15.7% increase in revenue within U.S. Healthcare Solutions and a 5.5% increase in revenue within International Healthcare Solutions. The company reported adjusted EPS of $3.34, up 16.8% year over year, beating the consensus of $3.22. Also Read: Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers Concurrently, Cencora agreed to acquire Retina Consultants of America, a management…
